fluorouracil has been researched along with Respiratory Distress Syndrome in 9 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Respiratory Distress Syndrome: A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Until ongoing phase III trials confirm these benefits, the current standard treatment for metastatic pancreatic adenocarcinoma remains single agent gemcitabine." | 4.81 | A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma. ( Bruckner, HW; Kozuch, P; Petryk, M, 2002) |
| "In order to determine whether preresectional chemoradiotherapy (CTRT) would influence resectability, local control, and survival of patients with localized pancreatic adenocarcinoma, a 5 1/2-year prospective study of 39 patients treated with preoperative radiation therapy, 5-Fluorouracil (5-FU), and Mitomycin C has been performed." | 3.68 | A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma. ( Agarwal, P; Eisenberg, BL; Engstrom, P; Hoffman, JP; Litwin, S; Paul, AR; Scher, R; Solin, LJ; Watts, P; Weese, JL, 1993) |
| "Patients with stage I or II esophageal cancer received preoperative radiation therapy (28-30 daily 1." | 2.73 | Acute respiratory disease syndrome with preoperative chronomodulated chemoradiotherapy in patients with esophageal cancer. Early termination of a phase I trial. ( Adenis, A; Lartigau, E; Mariette, C; Mirabel, X; Sarrazin, T; Triboulet, JP, 2008) |
| "A PPC was defined as pneumonia or acute respiratory distress syndrome within 30 days after surgery." | 1.42 | Serum Transforming Growth Factor-β1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy. ( Chang, DT; Cheng, JC; Hsu, CH; Hsu, FM; Huang, PM; Koong, AC; Lee, JM; Lu, SL; Tsai, CL; Wu, JK, 2015) |
| "Two fatal cases of interstitial pneumonitis rapidly evolving to pulmonary fibrosis are reported here." | 1.35 | Fatal pneumonitis induced by oxaliplatin. ( Arévalo Lobera, S; Azkue Gabilondo, M; Basterretxea Badiola, L; Egaña Otaño, L; Elejoste Echeberría, I; La Casta Muñoa, A; Melé Olivé, M; Sagastibeltza Mariñelarena, N, 2008) |
| "Data from 110 esophageal cancer patients treated between January 1998 and December 2003 were analyzed retrospectively." | 1.33 | Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. ( Ajani, JA; Cox, JD; Komaki, R; Liao, Z; Liu, H; Swisher, S; Tucker, SL; Vaporciyan, AA; Wang, SL; Wei, X, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, SL | 1 |
| Hsu, FM | 1 |
| Tsai, CL | 1 |
| Wu, JK | 1 |
| Lee, JM | 1 |
| Huang, PM | 1 |
| Hsu, CH | 1 |
| Koong, AC | 1 |
| Chang, DT | 1 |
| Cheng, JC | 1 |
| Arévalo Lobera, S | 1 |
| Sagastibeltza Mariñelarena, N | 1 |
| Elejoste Echeberría, I | 1 |
| Melé Olivé, M | 1 |
| Egaña Otaño, L | 1 |
| Basterretxea Badiola, L | 1 |
| La Casta Muñoa, A | 1 |
| Azkue Gabilondo, M | 1 |
| Dähn, D | 1 |
| Martell, J | 1 |
| Vorwerk, H | 1 |
| Hess, CF | 1 |
| Becker, H | 1 |
| Jung, K | 1 |
| Hilgers, R | 1 |
| Wolff, HA | 1 |
| Hermann, RM | 1 |
| Christiansen, H | 1 |
| Maruyama, N | 1 |
| Maruyama, K | 1 |
| Furukawa, J | 1 |
| Nagai, K | 1 |
| Tanaka, J | 1 |
| Katsumoto, Y | 1 |
| Yokouchi, H | 1 |
| Nakaguchi, K | 1 |
| Kinuta, M | 1 |
| Sue, F | 1 |
| Wang, SL | 1 |
| Liao, Z | 1 |
| Vaporciyan, AA | 1 |
| Tucker, SL | 1 |
| Liu, H | 1 |
| Wei, X | 1 |
| Swisher, S | 1 |
| Ajani, JA | 1 |
| Cox, JD | 1 |
| Komaki, R | 1 |
| Adenis, A | 1 |
| Mariette, C | 1 |
| Mirabel, X | 1 |
| Sarrazin, T | 1 |
| Lartigau, E | 1 |
| Triboulet, JP | 1 |
| Hoffman, JP | 1 |
| Weese, JL | 1 |
| Solin, LJ | 1 |
| Agarwal, P | 1 |
| Engstrom, P | 1 |
| Scher, R | 1 |
| Paul, AR | 1 |
| Litwin, S | 1 |
| Watts, P | 1 |
| Eisenberg, BL | 1 |
| Scholz, J | 1 |
| Steinhöfel, U | 1 |
| Dürig, M | 1 |
| Prause, A | 1 |
| Bause, HW | 1 |
| Hamper, K | 1 |
| Schulte am Esch, J | 1 |
| Kozuch, P | 1 |
| Petryk, M | 1 |
| Bruckner, HW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Dose Escalated Proton Beam Therapy or Photon Therapy for Resectable and Unresectable Esophageal Cancer[NCT03234842] | Phase 2 | 0 participants (Actual) | Interventional | 2017-10-30 | Withdrawn (stopped due to non-accrual) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fluorouracil and Respiratory Distress Syndrome
| Article | Year |
|---|---|
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow D | 2002 |
2 trials available for fluorouracil and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Acute respiratory disease syndrome with preoperative chronomodulated chemoradiotherapy in patients with esophageal cancer. Early termination of a phase I trial.
Topics: Adult; Aged; Chronotherapy; Cisplatin; Combined Modality Therapy; Demography; Esophageal Neoplasms; | 2008 |
Postoperative pulmonary complications in patients with esophageal cancer.
Topics: Aged; Brachytherapy; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Esophageal Neopl | 1993 |
6 other studies available for fluorouracil and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Serum Transforming Growth Factor-β1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compoun | 2015 |
Fatal pneumonitis induced by oxaliplatin.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoc | 2008 |
Influence of irradiated lung volumes on perioperative morbidity and mortality in patients after neoadjuvant radiochemotherapy for esophageal cancer.
Topics: Acute Lung Injury; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplat | 2010 |
[Pancytopenia and ARDS with high dose hepatic arterial infusion].
Topics: Aged; Antimetabolites, Antineoplastic; Cisplatin; Drug Combinations; Female; Fluorouracil; Gastrecto | 2003 |
Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.
Topics: Analysis of Variance; Camptothecin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorou | 2006 |
A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgi | 1993 |